Search Results

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VIII Physiological and pathological roles of AGPCRs in the periphery ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Adhesion GPCR GPR116/Adgrf5 controls a lineage of anti-thermogenic adipocytes with implications for adaptive thermogenesis during prolonged cold exposure Anastasia Georgiadi ADGRF5-mediated regulation of cardiac health and disease Douglas Tilley ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Cheng-Chih Hsiao1,2, Hendrik J. Engelenburg1, Joost Smolders1,3, and Jörg Hamann1,2 1Department of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; 2Department of Experimental Immunology, Amsterdam institute for Immunology and Infectious diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands; 3MS center ErasMS, Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands" About Cheng-Chih Hsiao "2012-2015: PhD in Immunology, University of Amsterdam; 2015-2019: Postdoctoral researcher, Amsterdam UMC; 2019-2022: Senior postdoctoral researcher, Netherlands Institute for Neuroscience; 2022 - present: Researcher associate, Netherlands Brain Bank" Cheng-Chih Hsiao on the web LinkedIn ReseachGate Adhesion GPCR GPR116/Adgrf5 controls a lineage of anti-thermogenic adipocytes with implications for adaptive thermogenesis during prolonged cold exposure Anastasia Georgiadi Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "El Merabhi Rabih1*, Karagiannakou Vasiliki1*, Kardinal Ronja2, Jäckstein Michelle3 Yvonne, Kumar Jha Ankush1, Krokidi Sissy Thodou1, Wachten Dagmar2, Heeren Jörg3, Herzig Stephan1, Georgiadi Anastasia1 *equal contributions , Institutions : 1. Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. Institute of Innate Immunity, University Hospital Bonn, University of Bonn, 3. Centre for Experimental Medicine, Institute for Biocehmistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf" About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology, Institute of Diabetes and Cancer (IDC). Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2015 - 2018 Postdoctoral fellow, Department of Adipose Tissue Biology, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2012 - 2015 Postdoctoral fellow, Department of Cell and Molecular Biology, Karolinska Institute, Sweden" Anastasia Georgiadi on the web Endocrine Pharmacology Google Scholar ADGRF5-mediated regulation of cardiac health and disease Douglas Tilley Abstract Only available for AGPCR 24 Attendees About Douglas Tilley "Research in the Tilley laboratory focuses primarily upon aspects of GPCR regulation of cardiac function, inflammation and remodeling during HF or following acute cardiac injury. Much of this work centered on elucidating novel mechanisms by which β-adrenergic receptors impact cardiac structure and function, and has evolved to encompass their roles in regulating immune cell response to acute cardiac injury or chronic stress. Additionally, the lab has begun to investigate potential roles for previously unrecognized cardiac-expressed GPCRs in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic directions for HF, including adhesion GPCRs (AGPCRs). In all, research in the Tilley lab spans molecular pharmacology to pathophysiology studies focused primarily in the cardiovascular realm." Douglas Tilley on the web Lewis Katz School of Medicine at Temple University < Previous Session Next Session >

Discover our comprehensive legal policies and disclaimers for Dr. GPCR Ecosystem, ensuring transparency and protecting your rights. Legal Policies and Disclaimers These legal documents and the agreement on Terms of Service (the “ATS”) for our websites ( Ecosystem.DrGPCR.com and DrGPCR.com ) (the “Website” or "Websites"). By using our Website, you agree to fully comply with and be bound by the following ATS each time you use our Website. Please review the following terms carefully. Dr. GPCR, Corp (“Dr. GPCR” or "DrGPCR") provides its Service (as defined below) to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com , DrGPCR.com . By accepting these Legal Policies and Disclaimers or by accessing or using the Service or Website, you acknowledge that you have read, understood, and agree to be bound by these Legal Policies and Disclaimers. If you are entering into this ATS on behalf of a company, business, or other legal entity, you represent that you have the authority to bind such entity and its affiliates to this ATS. If you do not have such authority, or if you do not agree with this ATS, you must not accept this ATS and may not use the Service. Dr. GPCR reserves the right to modify these Legal Policies and Disclaimers from time to time without prior notice. You can review the most current versions at any time on our Website. The revised terms and conditions will take effect upon posting. If you use the Service after this date, your continued use will constitute acceptance of the revised conditions. If any change to these Legal Policies and Disclaimers is not acceptable to you, stop accessing and using the Service. These agreements contain warranty disclaimers and other provisions that limit our liability to you. Please read these Legal Policies and Disclaimers carefully and in their entirety, as using, accessing, and/or browsing our Website constitutes acceptance of these terms and conditions. If you do not agree to be bound to each and every term and condition set forth herein, please exit our website immediately and do not use access and/or access it further. These Legal Policies and Disclaimers below must be accepted as a whole. You cannot accept one and ignore the others. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

< Back This is a Title 01 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

< Back This is a Title 02 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

Meet the sponsors who make the Adhesion GPCR Workshop 2024 possible, supporting global collaboration and innovation in GPCR research. Home Registration Full Agenda Venue Travel Tips Sponsors Special Issue on Adhesion GPCRs OUR SPONSORS Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Sponsor Us Platinum Sponsors Bronze Sponsors Collaborating partners Contact us for sponsorship Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program. Up About the venue Discover Cinvestav, the host venue for the upcoming workshop. Up Abstract Submission Submit your research abstracts following our guidelines to present at the conference. Up Traveling Tips Find essential tips about Mexico City, including transportation options and local insights.

Explore the scientific conference program at DrGPCR for cutting-edge insights in GPCR research. Stay updated with our program today! Welcome to Flash News—your fastest track to the latest updates in GPCR research, pharmacology, and biotechnology. Stay informed with breaking news, announcements, and key industry trends—all published here before they appear on social media. 🚀 Want full access? Become Premium! Unlock exclusive resources like the University Vault, in-depth courses, and weekly insights that go beyond the headlines. 👉 Become Premium Strategic Partners Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal December 8, 2025 Read full article Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery A GPCR imaging breakthrough that didn’t start in a grant proposal December 3, 2025 Read full article It started with a cold email. A young chemist, Dr. Johannes Broichhagen, was asked if he could synthesize a molecule “when you’re back in Munich.” That small moment pulled him into islet biology, confocal imaging, and a collaboration that would reshape how GLP-1R is visualized in real tissue. The new blog takes you behind the scenes — the London trip, the early confocal experiments, the pivot to chemical probes, and the trust-driven partnership that sparked a new era in GPCR imaging. If you care about chemical biology, receptor visualization, or building tools that actually work in complex systems, this one is worth reading. 🔗 Read the full story : https://www.ecosystem.drgpcr.com/post/how-collaboration-sparked-a-gpcr-imaging-breakthrough-in-chemical-biology Visualizing GPCRs in their native environment changes everything December 2, 2025 Read full article This week on The Dr. GPCR Podcast , we bring you Episode 2 of our three-part series with Celtarys Research — featuring chemist Dr. Johannes Broichhagen , whose work is redefining how we image GPCRs in real tissue. His team’s chemical probes enabled high-resolution GLP-1R visualization across systems — from pancreatic islets to in vivo two-photon imaging. Inside the episode: Chemical probes vs antibodies: specificity, stability, and live-cell performance Mapping GPCR surface pools with precision Tissue-level insights reshaping metabolic disease research What’s next: multiplex receptor labeling + AI-designed tools If GLP-1R biology, receptor trafficking, or advanced imaging are part of your work, this conversation belongs on your radar. 🎧 Listen to Episode 2 → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/chemical-probes-for-gpcr-imaging-and-internalization And stay tuned for Episode 3 with Celtarys. #GPCR #DrGPCR #metabolism #GLP1R #receptorbiology #fluorescenceimaging #drugdiscovery How GPCR Collaboration Built an Innovation Engine November 16, 2025 Dr. GPCR Podcast Read full article Collaboration isn’t a soft skill — it’s an innovation strategy. At Monash Institute of Pharmaceutical Sciences, a quiet experiment challenged the traditional PI-silo model: no private labs, shared infrastructure, pooled funding, and student rotations. The result? An ecosystem where GPCR innovation accelerated — not because of a single star scientist, but because the system itself made collaboration unavoidable. “No one had their own lab. That meant no one could build a fiefdom — and everyone had to talk.” — Michelle Halls This structure: Multiplied research capacity Attracted talent and funding Created a durable innovation hub This is more than a story — it’s a blueprint for GPCR science, biotech R&D, and CRO partnerships. 🎧 Listen to the full episode: Leadership, Luck, and GPCR Signaling 🔓 Learn more: Dr. GPCR Premium #GPCR #DrGPCR #DrugDiscovery #Innovation #ScienceLeadership #Collaboration Scientific careers aren’t just built on brilliance November 14, 2025 Dr.GPCR Podcast Read full article Scientific careers aren’t just built on brilliance—they’re shaped by curiosity, timing, and paying close attention. In this conversation, Michelle Halls reminds us of something every scientist eventually learns: hard work is essential, but noticing the unexpected often defines your biggest breakthroughs. She also names a truth we rarely acknowledge out loud—luck and timing matter. Many talented scientists leave the field not because they lacked skill, but because the right opportunity didn’t land at the right time. And that’s why attention to detail, persistence, and a bit of serendipity can change the trajectory of a research career. 🎧 Watch this moment — then catch the full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR Why does it matter where signaling happens inside a cell? November 13, 2025 Dr.GPCR Podcast Read full article Why does it matter where signaling happens inside a cell? This moment cuts straight to the heart of how many of us fell in love with GPCR biology — that realization that signaling isn’t random. It’s structured, organized, and spatially constrained. Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. This shift — from thinking about “pathways” to understanding localized signaling architecture — is what drove her to build a research career around spatial control of GPCR signaling. This isn’t just academic. The way signals are organized defines specificity, drug response, and potential for targeted therapies. If you work with GPCRs, this perspective changes how you design experiments and interpret data. 🎧 Watch this insight — or listen to the full conversation with Michelle.🔗 Full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling ✨ Join Premium: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR From Pipettes to Platforms: The Evolution of GPCR Research November 13, 2025 Dr. GPCR Podcast Read full article Back when GPCR assays were performed with single channel pipettes, failure wasn’t cheap. Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive. Today, automation and high-throughput platforms make it easy to forget how fragile discovery used to be. But that history matters. It shaped how we design experiments, make decisions, and lead teams. In this week’s Dr. GPCR Podcast blog, we unpack: How the manual era shaped experimental discipline Why technology changed what we ask, not just how we ask How scientists grow from technicians to strategic leaders 🎧 Read the full story and listen to the episode: https://www.ecosystem.drgpcr.com/post/from-pipettes-to-platforms-the-evolution-of-gpcr-research 🔓 Join Dr. GPCR Premium for deeper tools and insights: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR #DrugDiscovery #Pharmacology #Biotech How GPCR Spatial Signaling Sparked a Scientific Journey November 12, 2025 Dr. GPCR Podcast Read full article When boredom met obsession. It started as a summer project.A reluctant student pipetting through the day, expecting nothing more than routine lab work. But for Michelle Halls, that first experiment flipped everything. One spark led to a PhD at Monash University, a fellowship at University of Cambridge, and eventually a leadership role at the forefront of GPCR spatial signaling — a field reshaping how we understand receptor biology and drug discovery. Michelle’s story isn’t just about science.It’s about what happens when curiosity takes over. From reluctant intern to scientific leader From local signaling to spatial pharmacology From spark to strategy Read the full story here🔗 https://www.ecosystem.drgpcr.com/post/how-gpcr-spatial-signaling-sparked-a-scientific-journey 🔓 Want deeper GPCR insights? Join Dr. GPCR Premium for exclusive content, expert access, and community. #GPCR #DrGPCR #SpatialSignaling #Pharmacology #DrugDiscovery #ScientificLeadership #Biotech Every receptor tells a story November 11, 2025 Dr.GPCR Podcast Read full article Every receptor tells a story — but GPCRs speak a language of organization. Dr. Michelle Halls unpacks how GPCR signaling isn’t just about ligand–receptor interaction. It’s about where and how signaling happens — spatially confined microdomains, scaffolding proteins, and preassembled complexes that fine-tune the cell’s response. This level of organization defines specificity in signaling, and understanding it changes how we think about drug targeting and disease mechanisms. It’s a moment that reframes GPCR biology from static pathways to dynamic, organized systems — where complexity is the key to precision. 🎧 Watch this moment from our conversation, then listen to the full episode on leadership, luck, and GPCR signaling: 👉 https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR How sensitive can a GPCR really be? November 9, 2025 Dr. GPCR Podcast Read full article Think femtomolar. That’s the scale we’re talking about. This week on the Dr. GPCR Podcast , we sit down with Michelle Halls , leader of the Spatial Organisation of Signalling lab at Monash University. Her team is redefining how we understand GPCR signaling — not just at the cell surface, but in space, time, and disease context. In this episode, you’ll learn: How GPCR pre-assembly enables femto-level signal detection. Why receptor location matters as much as receptor type. How disease can hijack signaling organization — and what that means for drug discovery. Michelle’s work bridges elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling 🎓 Explore Dr. GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery #receptors #biotech #signaltransduction AI is changing how we think about structure, function, and discovery November 4, 2025 Dr. GPCR Podcast Read full article AI is changing how we think about structure, function, and discovery — but Jens Carlsson reminds us: the real test isn’t whether we can explain today’s data, it’s whether we can predict tomorrow’s results . In this clip, Jens unpacks a mindset shift that every computational scientist should hear. For decades, molecular modeling focused on explaining — rationalizing why a ligand binds, why a mutation shifts signaling, why a simulation behaves a certain way. But explaining is retrospective. Prediction is transformative. With tools like AlphaFold , his lab can now model receptor–peptide complexes in seconds — an achievement that once took months. Yet Jens’s caution stands: prediction must be proven. A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new function. That’s where the future of GPCR research lies — not in describing the past, but in anticipating it. Whether you’re running simulations, screening compounds, or designing next-gen molecules, this insight reframes what “success” in computational pharmacology really means. 👉 Watch the full episode: model predict discover #GPCR #DrGPCR If your model can’t change an experiment, what’s the point? October 31, 2025 Dr. GPCR Podcast Read full article If your model can’t change an experiment, what’s the point? That’s the standard Dr. Jens Carlsson sets in his lab at Uppsala University. For him, modeling isn’t just about elegant simulations; it’s about impact . The kind of impact that shows up in how experiments are designed, which compounds get prioritized, and what gets synthesized next. Carlsson’s lab doesn’t work in isolation. They collaborate deeply with medicinal chemists, pharmacologists, and biotech partners to create workflows that connect virtual screening to synthesis and bioassay. Every step has a purpose. Every prediction feeds into a testable hypothesis. But the real differentiator? The way they collaborate: strategically, transparently, and without ego. His team is clear about the capabilities and limitations of their models, an honesty that builds long-term trust across disciplines. In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional fluency is no longer optional. It’s the catalyst for turning insight into innovation. 🎧 Learn how Carlsson turns models into translational outcomes in this episode of the Dr. GPCR Podcast: model predict discover #DrGPCR #GPCR #CollaborationInScience #ComputationalChemistry #Pharmacology #DrugDesign “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” October 30, 2025 Terry's Corner Read full article “Technologies come and go. If that’s all you know, you’ll be out of the game fast.” In our AMA, Terry Kenakin shared timeless career advice for young pharmacologists navigating a fast-changing field: “Try to keep a finger on the pulse of as much as you can… that was one of the main reasons for doing Terry’s Corner. New ideas come up, and if we can encapsulate them and expose them, you can just hit a button, hear about it, and pursue it.” To stay relevant in the next decade, it’s not about chasing the latest assay or tool. It’s about building adaptive thinking—knowing where the field is moving and being ready to pivot with it. That’s what Terry’s Corner was built for: a space to turn decades of industry experience into short, targeted insights that keep you ahead of the curve. 🟢 Join Terry’s Corner → https://www.ecosystem.drgpcr.com/terry-corner ✳️ Next AMA Session: ⚠️ Today, Oct 30 | 12–1 PM EST #GPCR #DrGPCR #Pharmacology #DrugDiscovery #CareerDevelopment #Biotech #Mentorship #EarlyDiscovery #ScientificLeadership What happens when 40+ years of discovery experience get distilled into one conversation? October 29, 2025 Terry's Corner Read full article What happens when 40+ years of discovery experience get distilled into one conversation? That’s exactly what our first-ever AMA session with Terry Kenakin set out to do. Terry’s Corner was built to make advanced pharmacology practical: a space where scientists don’t just learn passively—they shape the curriculum and bring their toughest questions forward. As Terry shared during the AMA: “This is a labor of love. Pharmacologists are almost always working in systems they don’t fully understand. The more we can see, the better choices we make.” Through live Q&A, targeted modules, and short, focused lessons, Terry’s Corner gives discovery teams the frameworks to: Decode complex GPCR signaling. Rethink outdated models. Translate early data into better decisions. This is more than another course. It’s an open vault of knowledge. 🟢 Read More → https://www.ecosystem.drgpcr.com/post/accelerating-gpcr-drug-discovery-what-40-years-of-pharmacology-reveal ✳️ Next AMA Session: October 30 | 12–1 PM EST #GPCR #DrGPCR #Pharmacology #DrugDiscovery #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR&D #BiotechInnovation Ask-Me-Anything Session - Sept 18 - Trailer October 28, 2025 Terry's Corner Read full article Pharmacology doesn’t stand still—and neither should your toolkit. In the discovery phase, one overlooked kinetic parameter or a misjudged model can set your team back months . Precision in early decisions determines whether your molecule moves forward or stalls. That’s why we’ve built a dedicated space inside Terry’s Corner to get clear, evidence-based answers to the questions that shape your experiments and strategy. In this AMA session, you’ll learn how to: Decode GPCR signaling complexity using functional assay strategies Identify allosteric modulators before they derail downstream decisions Integrate kinetics early—before your program locks into costly pathways Rethink legacy screening frameworks through modern pharmacology This isn’t theory. It’s 45+ years of applied discovery experience from Terry Kenakin distilled into practical, modular lessons designed for scientists who need clarity fast. 🟢 Join Terry’s Corner → Terry's Corner | Dr. GPCR Ecosystem ✳️ BONUS — Live AMA Session: Get direct, unfiltered access to Terry. Bring your most challenging questions to our next Ask Me Anything session on October 30, 12–1 PM EST . ⚠️ Seats are limited. Don’t fall behind on what will shape the next decade of discovery. #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Biotech #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR&D #BiotechInnovation Irreversible kinetics = strategic lever in drug design. October 27, 2025 Terry's Corner Read full article Receptor pharmacology has evolved. Irreversible interactions are no longer niche curiosities — they’re strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery. Inside Terry’s Corner, you’ll gain access to focused, high-impact modules built for teams who need to engineer binding kinetics, not just potency . These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the tools to make smarter decisions earlier in the pipeline. Here’s what’s covered in this week’s lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic durability, and influence dosing intervals. Structured tissue penetration challenges — why high-affinity molecules stall at the periphery and how to optimize kinetic profiles for deeper reach. Quantifying irreversible activity (K_inact / K_I) — turning persistent binding into measurable design parameters that guide candidate optimization. Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault and stay ahead of the curve: ✳️ Courses by Terry | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Kinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDevelopment Can your model actually predict the outcome of a GPCR experiment? October 27, 2025 Dr. GPCR Podcast Read full article “Explain” is no longer enough. Can your model actually predict the outcome of a GPCR experiment? At Uppsala University, Dr. Jens Carlsson and his team are redefining what computational modeling means in drug discovery. Their lab doesn’t just simulate receptor-ligand interactions after the fact; they aim to forecast receptor behavior before the first assay is run. By integrating molecular docking, molecular dynamics, and machine learning, they design ligands with the goal to anticipate biological outcomes. This kind of predictive modeling challenges the traditional role of computation in pharmacology, where models have too often served as post hoc rationalizations. But Carlsson’s lab stands out for another reason: knowing when not to predict. His team is candid about the limits of their models. If the resolution isn't good enough, or if the data is too uncertain, they’re not afraid to say, “We don’t know.” That scientific humility (combined with deep collaborations with medicinal chemists and pharmacologists) is exactly what makes their predictions so useful. This episode is essential listening for anyone thinking seriously about translational pharmacology and the future of GPCR drug discovery. 🎧 Explore how predictive modeling is reshaping GPCR science in this Dr. GPCR Podcast episode: model predict discover #DrGPCR #GPCR #MolecularModeling #PredictivePharmacology #DrugDiscovery Persistent binding ≠ just covalent. October 24, 2025 Terry's Corner Read full article Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Dr. GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs October 23, 2025 GPCR Weekly News Read full article This week’s Weekly News breaks down how to control target engagement—so duration, penetration, and PK/PD separation serve your program, not sink it. Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “irreversible” in real systems, anticipating PK/PD decoupling, and using k_inact/K_I when Ki falls short. 🔹 Podcast Spotlight: Dr. Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where AlphaFold still needs a chaperone). If you’re advancing covalent or tight-binding candidates—or building models meant to predict, not narrate —this edition is built to shorten cycles and reduce surprises. Read the full Weekly News ➤ https://bit.ly/3KVlL4m If it helps your team, share it forward. #DrGPCR #GPCR Model. Predict. Discover. – Podcast Episode Release October 22, 2025 Dr. GPCR Podcast Read full article What if a failed experiment became the best thing that ever happened to your career? Dr. Jens Carlsson started his journey aiming to be a biotech engineer. But during a summer internship in protein purification, he faced a harsh reality: lab work wasn’t his strength. The experiments didn’t work, the data didn’t flow, and it was frustrating. But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why things weren’t working. A professor noticed and called it out in a recommendation letter. That unexpected moment of clarity redirected his path. Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based modeling to predict GPCR-ligand interactions, before they’re ever tested in the lab. The mindset shift? Stop explaining experiments after they happen. Start designing them to happen. His journey is a powerful reminder that the right career often reveals itself through “failure.” Follow what lights you up. Notice where your mind naturally goes. And don’t ignore the signs, it might be your real path calling. 🎧 Listen to Jens’ full story on the Dr. GPCR Podcast : https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover #DrGPCR #GPCR #CareerInScience #ComputationalBiology #DrugDiscovery #PhDLife 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 ... 7 🔔 Don’t Just Stay Updated—Stay Ahead Flash News gives you a glance at what’s happening right now in the GPCR world. But to go deeper—with full presentations, expert courses, and exclusive resources—you’ll need more than just a headline. 🎓 Go Premium and unlock: 200+ expert presentations in the University Vault Weekly News with in-depth insights Exclusive courses and masterclasses 👉 Upgrade to Premium Today

Join the GPCR Retreat 2023! Secure your spot now with our easy registration process. Don't miss out on this transformative experience. Retreat 2023 About Program Registration Logo Contest Committee Sponsors Registration Welcome to the Registration Portal for the 22nd GPCR Retreat taking place November 2-4, 2023 hosted at Fairmont Le Château Montebello in Montebello, Québec. We look forward to hosting you! REGISTRATIONS ARE CLOSED! Join the waitlist by emailing The Organizing Committee gpcrretreat@uottawa.ca Registration includes: Full Retreat Access All meals (please note that we will ask for dietary restrictions during the registration process) Social and networking events Early Bird Registration Fees (all fees are included): Trainee: CAD$ 360 Faculty: CAD$ 560 Industry: CAD$ 775 Early-bird Registration Deadline is September 8 at 11:59pm . Final Registration Deadline is September 21 (note that an extra CAD$ 100 will be added to the registration fee after the early bird deadline of September 8) Please follow the link here to register for the 22nd GPCR Retreat Hotel Accommodations The GPCR is proudly hosted at the Fairmont Le Château Montebello and a limited number of rooms at discounted rates have been reserved for your convenience. All hotel rooms can be booked directly with Montebello by clicking here . Please note that the meeting can accommodate a maximum of 200 individuals. Please book your rooms by October 2, 2023 , to take advantage of the discounted rates. Directions Detailed directions including directions from Ottawa, Ottawa airport, Montréal, Montréal airport, and car rental information, etc… can be viewed by clicking here . Scroll down to Maps & Information. Poster Sessions and Abstract Submissions Trainees of diversity groups are strongly encouraged to register for the meeting and submit an abstract for consideration for the trainee symposium and selected trainee short talks. Please submit your abstract by clicking here . Abstract submission deadline: October 2, 2023 If you attend the GPCR Retreat, click here Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Discover the mission, vision, and people behind the Dr. GPCR Ecosystem: uniting scientists, biotech, and innovators to advance GPCR research worldwide. Who We Are We are a global network of scientists, biotech innovators, pharma professionals, CRO leaders, and vendors—united by one mission: to make working on GPCRs easier, faster, and more collaborative. Dr. GPCR is both expert-led and community-first. We’re building together, with input from across the field. About Dr. GPCR Ecosystem We unite the GPCR Community to advance drug discovery Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools, and powerful connections. Join Free & Get Our Weekly News See Why it Matters 6,600+ followers 200+ Research Labs 1,500+ Scientists 50+ Biotech Companies Built by Scientists. Driven by Impact. Dr. GPCR began as a podcast. Now, it's a global ecosystem of scientists, biotech teams, CRO leaders, and trainees working to move GPCR science forward—together. We created this space to make trusted knowledge and collaborations easier to access—without noise, fluff, or hype. What We Believe The Ecosystem was built with five key beliefs: Scientific rigor first This is a space for data-driven work, not hype. Usefulness over flash Every piece of content and feature must be practical. Transparency builds trust We're open about who we are and what we do. Collaboration is key Progress in GPCR science requires a collective effort. Inclusion matters We welcome diverse voices, experiences, and expertise. We designed the Ecosystem to support your work —no matter where you are in your GPCR journey. Our Journey (So Far) From the first podcast episode to a global platform, it's all built by and for the GPCR community. 2020 First Podcast Episode Launched our podcast to share expert insights with the scientific community. 2021 2nd Annual Summit Increased our reach and impact with the GPCR Community 2022 Community Platform Expanded beyond content to create a dedicated space for GPCR scientists to connect. 2023 First Symposium Inaugural Dr. GPCR Symposium with over 100 attendees 2024 GPCR University Launched comprehensive courses and expert talks to deepen scientific understanding. 2025 Terry's Corner & Consulting Launched our exclusive program with Dr. Kenakin and offered to CROs consulting services See Full Timeline The Field Is Growing—but Fragmented As GPCR scientists, we know the problem: too much noise, too little time, and nowhere to connect that's built for us. We built Dr. GPCR to: Curate relevant data—not overwhelm you with it Connect researchers with CROs, peers, and biotech leaders Provide high-quality tools and expert insights on demand Whether you're in a lab, launching a startup, or prepping for due diligence, we built this for you. The GPCR Challenge Scientists waste an average of 12 hours per week searching for relevant GPCR research and connections. Our ecosystem cuts that time by 80%. You'll Be in Good Company From PhDs to CRO execs to rising biotech founders—this is a vetted, mission-aligned community built to help you move faster. Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools ✔ Academic researchers moving into translational work ✔ Teams preparing for fundraising or due diligence Expert Contributors Include: ✔ Terry Kenakin, with his exclusive series on GPCR pharmacology ✔ Sam Hoare, simplifying GPCR data analysis ✔ Global CROs and biotech leaders, contributing behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by Design Connects researchers, CROs, and biotech teams—not just profiles, real relationships. Results-Driven Every tool and content block is built to help you make a decision or move forward. ✔ GPCR-specific content ✔ Expert curation ✔ Vetted community What Joining the Ecosystem Looks Like 1 Join Free Sign up in seconds. You'll instantly receive the GPCR Weekly News (free version). 2 Get Verified We manually review each profile to ensure trust and scientific relevance. 3 Start Exploring Browse free content, community updates, and learn what's available. 4 Upgrade Anytime Premium unlocks exclusive courses, community features, and deeper insights. Start Your Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Board Member Anne M. Quinn Get in Touch Board Member Maria Waldhoer Get in Touch Co-Founder Attila Foris Get in Touch Board Member JoAnn Trejo Get in Touch Chief Matchmaker Mark Schmeizl Get in Touch Why Upgrade to Premium Everyone who joins receives the free Weekly News. Premium gives you everything else—the full toolbox for moving science forward. Free Membership Includes: ✔ Free version of GPCR Weekly News - straight to your inbox! ✔ Select news and content ✔ Ecosystem and podcast updates Premium Members Unlock: ✔ Full Weekly News access – All GPCR papers, events, jobs + expert commentary ✔ Dr. GPCR University – 5 on-demand GPCR courses, 1 project management course, 200+ expert talks ✔ Community tools – Member directories, messaging, and forums Partners Who Drive our Mission Partner Benefits Visibility to GPCR experts Direct connections Industry insights Explore Partnership Opportunities Ready to Join the Movement? Start free. Upgrade when you're ready. Dr. GPCR helps you stay ahead of the curve in science and strategy. Unlock Premium Access Join Free Now

Submit your partnership request with our easy-to-use online form. Join Dr. GPCR Ecosystem and collaborate with us to make a positive impact. Strategic Partners Back to Partners List Submit Thanks for submitting! We'll get back to you to set up a meeting.

Join Dr. GPCR and become an Ecosystem Contributor! Discover how you can make a positive impact on the field and inspire others to do the same. Ecosystem Contributor - Coming Soon -

Turn GPCR discovery chaos into clarity—Yamina’s Corner offers expert GPCR strategy, CRO guidance, and tailored scientific support to accelerate your pipeline. Home About News Get in Touch Welcome Turn GPCR Chaos Into Insights Expert strategic and scientific consultancy to accelerate your pipeline Book My Consultation Critical Bottlenecks in Your GPCR Pipeline ❌ Overwhelming pharmacology Data ❌ Suboptimal CRO Partnerships ❌ Stalled Pipeline Progression ❌ Uncertainty in GPCR Investments Advisory Focus Areas Expert support for Biotech innovators, VC investors and CRO partners Biotech Pipeline Acceleration For Biotech Leaders & Scientists Actionable Data Insights: Translate complex GPCR pharmacology into clear decisions for lead optimization and candidate selection. Accelerated Program Progression: Design robust assay cascades and establish key go/no-go points to speed up your pipeline. Optimized CRO Collaboration: Streamline internal R&D and external CRO workflows to prevent delays and ensure preclinical success. Fuel Discovery VC Due Diligence & De-risking For Venture Capital Firms De-risk GPCR Investments: Identify critical scientific red flags and technical gaps in GPCR assets before committing capital. Actionable Scientific Validation: Ensure target companies execute the right GPCR pharmacology experiments to generate robust, decision-making data. Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic potential to inform investment strategy. Fast-Track Discovery CRO Partnership & Optimization For Contract Research Organizations Elevate Scientific Offerings: Refine and optimize your GPCR assay platforms and in vitro models to deliver superior data quality and results. Enhance Client Project Delivery: Streamline workflows and improve scientific execution to increase client satisfaction and secure repeat business. Differentiate Your Market Position: Showcase your specialized GPCR expertise to stand out from competitors and attract high-value biotech and pharma partners. Power Discovery How We Work: Your Path to GPCR Success 1 Initial Strategic Alignment We begin with a focused discussion of your current GPCR program and critical challenges, identifying precise areas for collaboration. 2 Define Actionable Objectives Together, we clarify specific, measurable goals, from target validation and assay development to CRO selection or portfolio strategy, ensuring a tailored approach. 3 Collaborative Execution & Impact I integrate directly into your discovery process to remove roadblocks, enhance execution, and generate actionable scientific data, driving confident decisions and sustained preclinical progress. Advance My Discovery My Approach: Precision Guidance for GPCR Programs I provide the focused, scientific expertise that accelerates complex GPCR discovery programs, ensuring clarity and de-risking your path from target to candidate. I integrate seamlessly with biotech, VC, and CRO teams as a trusted, objective partner. Integrated Strategic Partnership We collaborate directly with your scientific and leadership teams. This partnership prevents bottlenecks and optimizes resource allocation, ensuring every strategic decision efficiently propels your program forward and aligns with critical business objectives. Biology-First, Data-Driven Solutions Every recommendation is rooted in GPCR biology, pharmacology experience. This provides evidence-based strategies leveraging deep GPCR expertise to overcome specific scientific challenges and maximize your program's potential. Accelerated Preclinical Progression I streamline critical operational processes, from advanced assay design and CRO management to rapid go/no-go decision-making. This focused execution accelerates preclinical milestones and maximizes the efficiency and return on your R&D investment. Core Values: The Foundation of Every Successful Partnership My advisory is built on principles that ensure clarity, minimize risk, and drive enduring results in GPCR drug discovery. Scientific Integrity Every recommendation is rigorously evidence-based, not reliant on assumptions. This ensures robust, defensible decisions that de-risk your program from early discovery to regulatory milestones. Operational Discipline I instill structure and consistency across every phase of your discovery process. This approach eliminates inefficiencies and standardizes workflows, accelerating your path to a preclinical candidate. Collaborative Partnership I operate as an embedded, invested partner with your team. Your program's success is my priority, fostering a transparent, results-driven environment that maximizes collective expertise and accelerates progress. About Yamina A. Berchiche I'm Yamina A. Berchiche, and I understand the intricate challenges of GPCR drug discovery. Small missteps can derail entire programs: underperforming assays, off-track CROs, and data that fails to drive decisions. That's precisely where my expertise becomes your strategic advantage. With over two decades dedicated to GPCR pharmacology across biotech, academia, and the non-profit sector, I bring unparalleled scientific depth and operational precision to every project. My work focuses on integrating directly with your team as a strategic partner. Whether it's optimizing CRO selection, building robust internal capabilities, or translating complex data into decisive program advancements, I help you eliminate friction, align efforts, and accelerate your path to success. As the founder of Dr. GPCR, I also offer a unique, broad perspective and trusted relationships within the field. This allows me to connect you with critical insights and key collaborators, further accelerating your progress in GPCR drug discovery. Let's Talk Discovery What Partners Say Here’s what it’s like to work together — from people I’ve supported on both sides of the bench. Anne Marie Quinn, CEO Montana Molecular Before working with Yamina, we were generating high-quality data across biotech programs but often navigating evolving expectations and goals from different stakeholders. After partnering with her, communication became clearer, deliverables were better defined, and collaboration across teams ran more smoothly. She helped streamline complex projects and made the CRO–client relationship more effective and productive. Terry Kenakin, PhD UNC Chappel Hill Yamina brings scientific clarity, leadership, and precision execution to complex pharmacological programs. I’ve worked with her on several discovery programs; in fragmented programs she bought clarity and decision points that produced much better candidate progression. I am always delighted to work with Yamina as it always leads to an overall better and harmonious discovery program. Murat Tunaboylu, CEO Antiverse Before engaging Yamina, our team faced hurdles in navigating complex early discovery decisions. We had critical program choices ahead and needed clear direction. Bringing her in was a turning point. We swiftly made confident progress on a pivotal program and gained absolute clarity on our next strategic focus. Yamina was instrumental in unifying our scientific and operational teams, fostering crucial alignment and driving decisive momentum across every aspect of execution. Book Book My 30 Minutes Strategy Call Menu Home Services About News Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch Connect LinkedIn Podcast Dr. GPCR Calendly ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session IX / Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane targets, such as ion channels, remains a significant challenge. Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures. This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody discovery. Several case studies of GPCR and other multi-pass transmembrane targets are presented, including GPRC5D, Claudin 6 and Napi2b. These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity compared to other methods. These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug resistance and tumor escape. About Gavin Zhang Gavin is a currently a director of business and operations at Novoprotein Scientific. His research experience includes phylogenetics and cancer epigenetics. Gavin Zhang on the web LinkedIn < Previous Session Next Session >

Find answers to all your questions about the Dr. GPCR Ecosystem: courses, podcasts, memberships, events, and more. Frequently asked questions University Vault Premium Pricing GPCR Masterclass YC-Biotech YC-VC YC-CRO Terrys Corner Media Partner Foundry General University Dr.GPCR Podcast What is the University Vault? An exclusive, members-only archive of expert talks from past DrGPCR events, plus comprehensive courses and career resources. Who is it for? Researchers, scientists, postdocs, graduate students, and professionals in GPCR-related fields looking to advance their careers. Is the content still relevant? Absolutely. These presentations provide foundational and advanced insights that continue to inform current research, plus we continuously add new content. How often is new content added? New sessions are uploaded after each DrGPCR Summit or Symposia, plus we regularly add new courses, news, and update career resources.

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Leaving for City Center Coming Soon < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Registration & Coffee with light breakfast < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session II AGPCR signaling pathways and trafficking Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Shen,Tingzhen; Bernadyn,Tyler; Kwarcinski, Frank; Gandhi, Riya; Tall, Greg. University of Michigan." About Yuling Feng "I am currently a postdoctoral research fellow working with aGPCR pharmacology and physiology in rodents." Yuling Feng on the web LinkedIn The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Serafin D. Stephen, Caron Kathleen M Department of Cell Biology and Physiology at UNC Chapel Hill 111 Mason Farm Road, MBRB, CB 7545. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 27599" About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing (GAIN) domain of Latrophilin 3 receptor under the mentorship of Dr. Antony Boucard. I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic endothelial cells (LECs), a cellular model with unique junction arrangements where aGPCRs are mainly unexplored. " Monserrat Avila Zozaya on the web LinkedIn Caron Lab Antony Boucard Lab Dr. GPCR Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Yamamoto, Takahiro 1,2*, De Araujo Farias, Virginea 1, Zhu, Dan3; Kuranaga, Yuki1, Parag, Rashed Rezwan 1,4,, Osuka, Satoru1,5 1 Department of Neurosurgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2 Department of Neurosurgery, Kumamoto University, Kumamoto, Japan 3 Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA 4 Graduate Biomedical Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA " About Erwin G. Van Meir "Dr. Erwin Van Meir is a professor in the UAB Department of Neurosurgery. He was trained in molecular biology at the Universities of Fribourg and Lausanne, Switzerland where he obtained his Ph.D. in 1989. Dr. Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined the faculty of Emory University in 1998. His research interest lies in understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics that will improve patient survival. Van Meir’s research examines how genetic alterations and hypoxia induce changes in cell biology that promote tumor formation with particular emphasis on adhesion GPCRs ADGRB1 and ADGRB3. Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor pathway and the epigenetic reader MBD2 (methyl CpG binding protein 2). His research aims to translate these novel agents to testing in clinical trials with the hope to develop novel medicines for cancer treatment." Erwin G. Van Meir on the web Google Scholar Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Abstract "ADGRG6 is a member of the adhesion G-protein-coupled receptor (aGPCR) family, known to play a role in myelination, placentation, blood vessel, and inner ear development. Like many other aGPCRs, ADGRG6 undergoes autoproteolysis at the GPCR-autoproteolysis site (GPS) enclosed within the larger GAIN domain to generate the N-terminal (NTF) and C-terminal fragments (CTF). These cleaved fragments join to form the heteromeric ADGRG6 receptor complex. ADGRG6 NTF has multiple extracellular domains like CUB, PTX, SEA, hormone binding domain, and the GAIN domain, which regulate G-protein signaling by binding to extracellular matrix proteins and mechanotransduction. The short stachel sequence at the extreme N-terminal end of the CTF functions as a tethered agonist to activate cAMP signaling. GPCR signaling and trafficking can be regulated by several different post-translational modifications (PTM). Stehlik et al. have reported that ADGRG6 expressed in lipopolysaccharide stimulated human umbilical vein endothelial cells is N-glycosylated. However, it is unclear which domains of ADGRG6 are N-glycosylated and how this might affect the overall molecular pharmacology of the receptor. Furthermore, are there spatial roles of N-glycosylation in ADGRG6 processing, trafficking, signalling and in-vivo functions? To address these gaps in knowledge, we used biochemical and cell-biological approaches using cell-lines overexpressing wild-type and N-glycosylation mutants of ADGRG6. We observed that N-glycosylation specifically takes place in the NTF and not the CTF of ADGRG6. Our results demonstrate that specific N-glycan residues in different domains of the extracellular NTF of ADGRG6 have distinct roles in ADGRG6 autoproteolysis, furin cleavage, membrane trafficking, and G-protein signalling. In the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development using zebrafish models." Authors & Affiliations "Anandhu Jayaraman: Department of Biology, Ashoka University Prabakaran Annadurai: Department of Biology, Ashoka University. Currently: University of Leipzig Mansi Tiwari: Department of Biology, Ashoka University. Currently: University of Aberdeen Priyadatha Sajan: Department of Biology, Ashoka University, Currently: University of Groningen Nayonika Chatterjee: Department of Biology, Ashoka University Prateek Sibal: Department of Biology, Ashoka University" About Pal Kasturi "I received my bachelor’s degree in Physiology from Presidency College, University of Calcutta and went on to complete my masters from Madurai Kamaraj University. During my PhD training, I worked in the laboratory of Dr. Kathryn Defea at the University of California, Riverside. For my PhD thesis, I worked on non-canonical, scaffold driven signaling by protease activated receptor-2 (PAR2). I joined University of Texas Southwestern Medical Center, for my postdoctoral training. Here, I worked on the regulation of the Sonic Hedgehog pathway by GPCRs which localized to the primary cilia. I then joined the laboratory of Dr. Velia Fowler, at the Scripps Research Institute, as a Judith Graham Poole postdoctoral fellow to work on the role of cytoskeletal proteins in megakaryocyte to platelet differentiation. I joined the Department of Biology at Ashoka University in 2020 as an assistant professor." Pal Kasturi on the web Ashoka University < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Coffee Break with lights snacks Complimentary < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VIII * Physiological and pathological roles of AGPCRs in the periphery The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Tobias Langenhan, Nicole Scholz, Genevieve M. Auger, Helen Strutt, David Strutt" About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc. Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim Abstract "G-protein coupled receptor 110 (ADGRF1, GPR110), an adhesion GPCR recently deorphanized, plays an important role in in the development of neurons and cognitive function. Synaptamide, an endogenous ligand for GPR110, binds to the N-terminal G-protein autoproteolysis-inducing (GAIN) domain of GPR110, and activates GPR110/cAMP signaling. This activation promotes neurogenic differentiation of neural stem cells, neurite growth, and synaptogenesis of developing neurons. In addition, a significant role of GPR110 in blood brain barrier (BBB) function has been discovered. GPR110 is highly expressed in mouse and human NPCs and neurons, while its expression was absent in astrocytes. GPR110 is also highly expressed in the kidney, however, little is known about the function of this receptor in renal physiology. To extend our understanding of the role of GPR110 signaling in kidney, we evaluated the urine albumin level in mice devoid of GPR110 gene (GPR110 KO) compared to the wild type (WT). To provide the molecular basis for the renal phenotype, we analyzed in parallel differential expression of kidney proteins in GPR110 KO and WT mice by label-free LC-MS/MS and pathway analysis. We found that the albumin to creatinine ratio was significantly elevated in urine samples obtained from GPR110 KO mice, indicating glomerular filtration dysfunction. The change in protein expression of key proteins including VEGFA is associated with the abnormal renal phenotype of albumin urea in GPR110 KO mice. In addition to the central nervous system phenotype such as learning and memory deficit and BBB dysfunction, our study revealed a new renal phenotype associated with lack of GPR110 signaling. " Authors & Affiliations "Laboratory of Molecular Signaling, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA" About Hee-Yong Kim "Senior Investigator and Chief of the Laboratory of Molecular Signaling at NIAAA, NIH" Hee-Yong Kim on the web NIH The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Abstract "All animals develop through the recognition, adhesion, and fusion of a differentiated sperm and egg. Although fundamental, the evolution of gametogenesis and fertilization in animals is poorly understood. Recently, evidence for sex has been described in choanoflagellates, the closest living relatives of animals. Under nutrient depletion, the model choanoflagellate Salpingoeca rosetta forms distinct cell types that aggregate, fuse, and undergo meiotic recombination. Additionally, the bacterium Vibrio fischeri also induces mating in S. rosetta cultures, suggesting that multiple environmental cues can trigger sex. Importantly, the signaling pathways underlying sexual reproduction in these different contexts have not been investigated. In this study, we report the discovery of an adhesion GPCR, named Cupidon, that regulates the switch from vegetative growth to sexual reproduction in S. rosetta. We found that the knock-out of cupidon induces a gain in cell adhesion and cell fusion, resembling the mating behavior of wild-type cells under nutrient depletion. Cupidon mutants, similar to starved wild-type cells, upregulate various extracellular matrix-related genes, including teneurins and metalloproteases. Finally, we showed that nutrient availability controls the dissociation of the N-terminal fragment in Cupidon. Together, our results suggest that Cupidon prevents sexual reproduction in S. rosetta under high nutrient availability, by inhibiting genes involved in gamete recognition. " Authors & Affiliations "King Nicole, Howard Hughes Medical Institute and Department of Molecular and Cell Biology, University of California Berkeley" About Alain Garcia De Las Bayonas "Hi everyone! I am currently finishing my postoc in the laboratory of Pr Nicole King at UC Berkeley where I am studying the evolution of GPCR families in choanoflagellates, the sister group of animals. I have a particular interest in understanding the premetazoan function of adhesion GPCRs." Alain Garcia De Las Bayonas on the web King Lab Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust Abstract Only available for AGPCR 24 Attendees Authors & Affiliations Coming Soon About Gabriela Aust Coming Soon Gabriela Aust on the web Coming Soon < Previous Session Next Session >

Discover top GPCR Courses for your educational journey. Explore a curated list of GPCR Courses to enhance your knowledge and career. Stay at the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay design, and pharmacology—skills you won't find in any textbook or paper. ⧖ 20+ Hours of Expert Training ↓ Downloadable Resources ◕ New Courses added Quarterly Get Access to GPCR Courses Learn in 3 Simple Steps Free trailers coming soon Preview every masterclass before joining Unlock full access Get Premium for complete library access Learn anytime, anywhere Access on-demand from any device Join Premium Today Unlock Insider Access to GPCR Science! Free updates, exclusive previews, and highlights from our Masterclasses and Vault. First name Last name Email* Join Our Mailing List Count me in! * Explore the Masterclasses Trailers are free. Full classes require Premium. Filter by Category Filter by Level Filter by Instructor Watch Now INSTRUCTOR Heading 5 I'm a paragraph. Click here to add your own text and edit me. It's easy. Read More INSTRUCTOR Heading 5 I'm a paragraph. Click here to add your own text and edit me. It's easy. Read More INSTRUCTOR Heading 5 I'm a paragraph. Click here to add your own text and edit me. It's easy. 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 ... 100 Learn directly from world leaders in GPCR research Access exclusive training from the scientists shaping the future of GPCR drug discovery Dr. Terry Kenakin Terry's Corner Author of 'A Pharmacology Primer', the definitive GPCR reference used by labs worldwide. Former GSK principal research investigator with 40+ years of industry experience. Dr. Sam Hoare Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay design strategies. Pioneer in quantitative pharmacology methods. Dr. Yamina Berchiche Dr. GPCR Community builder for scientists with expertise in GPCR project strategy and translational applications. Unlock All 20+ GPCR Masterclasses – Save 95% Individual courses cost $300–600 each. With Premium, you get everything for just $249.99/year (less than $1/day). 20+ Hours of GPCR Masterclasses Downloadable Resources & Q&A Replays Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay can cost $10,000+ in reagents and months of time. Think of Premium as insurance against wasted experiments and failed drug leads. Best Value Premium Yearly $249.99 $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. What Scientists Are Saying Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere Anonymous Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field Anonymous The content had enough depth to satisfy the hunger for theory while being full of practical knowledge Anonymous The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology Anonymous Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him Anonymous Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. Anonymous What are the benefits of becoming a member of Dr.GPCR? As a member, you can access: Dr.GPCR Podcast videos Live GPCR events Weekly classified GPCR news Contributor articles As a premium member, you can access all the free features plus: GPCR courses with a 25% discount Private groups 30+ Symposia recorded talks GPCR Job listings GPCR Event listings Direct access to members of the GPCR community How do I sign up for a membership? To sign up, click the 'Log In/Sign Up' button at the top of the homepage and fill out the registration form. Once your registration is complete, you will receive a confirmation email. Why do I need to fill out a form and wait for approval? We carefully screen anyone signing up to the Ecosystem to ensure they are real humans working on GPCRs. We want to keep our community exclusive to the field, so we need as much information as possible to verify your identity. How long will the Sign-Up process take? We could take up to two (2) business days. I’m just a student starting in the field. Can I sign up to the Ecosystem? Yes, everyone interested in the field is welcome to join. Please let us know about this while filling out the registration form. Why are personnel from US governmental agencies excluded from the free membership? Employees of any branch or department within the US government are not eligible for the free membership. Verification methods can vary but might require a work email address, an official ID, or other employment documentation during the sign-up process to confirm whether the individual is employed by a US governmental agency. If there's any uncertainty about eligibility, the best action is to contact us at hello@drgpcr.com. How much does the premium membership cost? The premium membership is priced at $249.99 per year. We have a 90% discount for people who live and work in developing countries and a 15% discount for team memberships, a minimum of 5 seats. You can also access a 25% discount on our Dr.GPCR University courses as a premium member. Can I upgrade from a standard membership to a premium membership? Yes, you can upgrade at any time. Log into your account, go to the Pricing section, and select the option you’d like to choose. Your premium benefits will be activated immediately. Is there a free trial for the premium membership? Yes, we offer a 30-day free trial for new premium members. You can sign up for the trial on the premium membership page. If you choose not to continue, you can cancel anytime before the trial ends without being charged. How do I cancel my membership? You can cancel your membership by following these steps: Go to My Account. Select the tab My Subscriptions. Select the membership you want to cancel and click Cancel Subscription. If you are a premium member, your access will remain active until the end of the current billing cycle. Will my membership renew automatically? If you choose the yearly payment option, your membership will renew automatically to ensure uninterrupted access. What should I do if I forget my password? Click on the 'Forgot Password' link on the login page, and follow the instructions to reset your password. You will receive an email with a link to create a new password. Who can I contact for more help with my membership? If you need further assistance, please email our support team at hello@drgpcr.com. We are here to help! The GPCR Field Is Advancing Fast – Don't Fall Behind Stay ahead in drug discovery with insights from the world's top GPCR experts. Get Access Today!

Awkward... This page isn’t available. Go Home

< Back Your GPCR Order Has Arrived! ❇ Feb 10 - 16, 2025 🚀 GPCR Pals, Get Ready to Elevate Your Expertise! Welcome back to your exclusive GPCR Weekly Newsletter! We’re thrilled to unveil our ever-expanding course roster—designed to help you stay at the cutting edge of GPCR research. New topics, expert-led sessions, and hands-on learning opportunities await! 🎓 Kicking Off Today: Dr. Terry Kenakin ’s hands-on workshop, The Practical Assessment of Signaling Bias . Didn’t sign up? Don’t worry— registrations are NOW OPEN for the 2025 Dr.GPCR University Courses! This is your chance to learn directly from our world-renowned experts. Come back regularly as we are adding courses each month. Email us if you'd like to teach or if you'd like to learn more about any particular topic. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April 10, 2025 (Thursdays, 10:00 AM–12:00 PM EST). Watch Dr. Kenakin as he introduces the key concepts of this brand-new course. During these four sessions, you'll dive into: Advanced pharmacokinetic modeling The Druglike Quality of Chemical Entities Drug Absorption 💡 Looking for workshops? We’ve got you covered! ✅ Practical Quantification of Allosteric Modulation – May 1, 2025 ✅ Applying the Black/Leff Operational Model to Predict Agonism – October 2, 2025 Premium Members save 25% on enrollment. Reserve Your Spot Now! 🔗 Register Today . 🔥 Act Fast – Only 25 Spots Available! ⚡ Don’t miss out! Premium Members save 25% on enrollment! Secure your spot today! Highlights of the Week How Ligands Achieve Biased Signaling toward Arrestins Stéphanie Gaillard , Neha Verma , Leisha A Emens , et. al. A combined in silico approach to design peptide ligands with increased receptor-subtype selectivity Adam Zech , Victoria Most , René Staritzbichler , et. al. A2B adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C Qin Wang , Wenwen Hao , Jing Li , et. al. Classified GPCR News Let’s dive into the Classified GPCR News from February 10th to 16th, 2025 Industry News Pain targets in ion channel pathways: an Innovation Distillery spotlight ‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic Secures Massive $185M PIPE Financing for Clinical Programs Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist Call for GPCR Papers NEW Special Issue on Adhesion GPCRs GPCR Events, Meetings, and Webinars March 19, 2025 | Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite March 17 - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology April 3 - 6, 2025 | ASPET 2025 April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR Annual Meeting 2025 May 12 - 15, 2025 | PEGS 2025 May 15 - 17, 2025 | 23rd GPCR Retreat 2025 May 20 - 22, 2025 | SLAS Europe 2025 NEW May 20 - 22, 2025 |4th GPCRs-Targeted Drug Discovery Summit June 22 - 26, 2025 | G Protein-coupled Receptor Kinases and Arrestins NEW December 16 - 18, 2025 |Pharmacology 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Structural Biologist Associate Director/Director, Platform & Hit-ID Chemistry Lead Junior associate position and a PhD/post-doc level position Postdoctoral Position And PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Senior Principal Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing GPCR Activation and Signaling Lineage-Specific Class-A GPCR Dynamics Reflect Diverse Chemosensory Adaptations in Lophotrochozoa β-arrestin 1 and integrin-linked kinase interact in epidermal keratinocytes and regulate cell motility The regenerative wound healing effects and molecular mechanism of Isaria cicadae Miquel rice fermentation extract A2B adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C GPCRs in Cardiology, Endocrinology, and Taste N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation GPR180 Reduces Adiposity by Inhibiting Lipogenesis and Fatty Acid Uptake in Adipocytes Derivation of hiPSC line (ICADRB2i007-A-3) from an individual with osteoporosis linked to ADRB2: c.46G > A GPCRs in Neuroscience Effects of chemogenetic virus injection and clozapine administration in spinal cord injury GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain after nerve injury Hypothalamic opsin 3 suppresses MC4R signaling and potentiates Kir7.1 to promote food consumption Reviews, GPCRs, and more How Ligands Achieve Biased Signaling toward Arrestins Structural and Molecular Insights into GPCR Function A combined in silico approach to design peptide ligands with increased receptor-subtype selectivity Ligand-Independent Spontaneous Activation of Purinergic P2Y6 Receptor Under Cell Culture Soft Substrate 🔎 GPCR KEYWORDS Class-A G protein-coupled receptors , Lophotrochozoa , echinoderms , Arrestins , ILK , directional migration , epidermis , keratinocytes , scaffold proteins , β-arrestin , Hippo pathway , IMFRE gels , Regenerative healing , Skin repair , Wound healing , A2B adenosine receptor , Calcium , G protein , GPCR , Gi , Gq , Gs , N-homocysteinylation , Adiposity , Fatty Acid Uptake , Lipogenesis , Induced pluripotent stem cells , Osteoporosis , Reprogramming , AAV5-hSyn-hM3Dq-eYFP , Clozapine , DREADDs , Gq signaling pathway , Neuroregeneration , EPSC , GLT-1 , GPR37L1 , SPM , astrocytes , maresin 1 , microglia , nerve injury , neuropathic pain , spinal cord dorsal horn , OPN3 , cAMP signalin g , MC4R , docking , opioid , peptide ligand design , protein design , Ca2+ oscillation , GPCRs , basal activity , purinergic receptor , substrate stiffness < Previous Next >

< Back Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 Hi friends! Welcome to our weekly update! This week's GPCR roll-up includes the latest insights, research discoveries, and advancements. We'll also preview upcoming courses designed for both experienced researchers and newcomers. 🚀 Develop New GPCR Skills Join Dr. Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential insights into: 🔹 Drug Development Basics – PK-PD insights, absorption, and drug properties 🔹 Clearance & Metabolism – Distribution, renal/hepatic pathways, and elimination 🔹 Safety First – Identifying toxicity risks and drug-drug interactions ⏳ Availability is limited. Register now and shape the future of drug discovery! Premium Members enjoy a 25% discount Secure Your Spot Today! Tune in to Ep.160 of the Dr. GPCR Podcast 🎧 Join Remi Janicot as he shares his educational journey, passion for basketball and science, and career decisions. He discusses biased signaling in GPCR research, developing biosensors for G protein activity, networking, mentorship, PhD resilience, COVID-19 challenges, and his aspiration to transition into biotechnology investment opportunities. Highlights of the week Structural insights into prolactin-releasing peptide receptor signaling and G-protein coupling selectivity Zhangsong Wu , Chen Qiu , Geng Chen , et al. Single-Molecule Insights into GPCR Conformational Landscapes Rajan Lamichhane Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer Stefan Diethelm , Luboš Remeň , Olivier Corminboeuf , et al. Classified GPCR News Let’s dive into the Classified GPCR News from February 17th to 23rd, 2025 Industry News Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist Revolutionizing Protein-Ligand Simulations: OpenMMDL's Open-Source Approach The Rapid Push into Radiopharmaceuticals in Oncology and What’s Next Call for GPCR Papers Special Issue on Adhesion GPCRs GPCR Events, Meetings, and Webinars March 19, 2025 | Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite - Online March 17 - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK April 3 - 6, 2025 | ASPET 2025 - USA NEW April 14 - 17, 2025 | 20th Drug Discovery Chemistry 2025 - USA April 24 - 27, 2025 | American Physiology Summit 2025 - USA April 25 - 30, 2025 | AACR Annual Meeting 2025 - USA NEW May 1 - 2, 2025 | 5th Ace Drug Discovery Summit 2025 - USA NEW May 12 - 15, 2025 | ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 - USA May 12 - 15, 2025 | PEGS 2025 - USA May 15 - 17, 2025 | 23rd GPCR Retreat 2025 - USA May 20 - 22, 2025 | SLAS Europe 2025 - Germany May 20 - 22, 2025 |4th GPCRs-Targeted Drug Discovery Summit - USA June 22 - 26, 2025 | G Protein-coupled Receptor Kinases and Arrestins - USA December 16 - 18, 2025 |Pharmacology 2025 - UK July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology - Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Junior associate position and a PhD/post-doc level position - Eli Lilly and Company Postdoctoral Posit ion And PhD Position - Autonomous University of Barcelona GPCR Molecular Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic Adhesion GPCRs A force-sensitive adhesion GPCR is required for equilibrioception GPCR Activation and Signaling Extensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR Light intensity-dependent arrestin switching for inactivation of a light-sensitive GPCR, bistable opsin Diapause hormone receptor affects larval growth and embryonic development in the multivoltine strain of Bombyx more Profiling Allosteric Modulators of CB1R with an Allosteric Fluoroprobe GPCRs in Cardiology, Endocrinology, and Taste Immunolocalization and quantification of the phoenixin and GPR173 in the gastrointestinal tract of Holstein-Friesian bulls Derivation of hiPSC line (ICADRB2i007-A-3) from an individual with osteoporosis linked to ADRB2: c.46G > A GPCRs in Neuroscience Cortical astrocyte activation triggers meningeal nociception and migraine-like pain GPCRs in Oncology and Immunology Spatial analysis of a complete DIPG-infiltrated brainstem reveals novel ligand-receptor mediators of tumour-to-TME crosstalk Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer The extracellular matrix protein type I collagen and fibronectin are regulated by β-arrestin-1/endothelin axis in human ovarian fibroblasts Methods & Updates in GPCR Research Histamine-modulated wettability switching in G-protein-coupled receptor inspired nanochannel for potential drug screening and biosensing Reviews, GPCRs, and more Single-Molecule Insights into GPCR Conformational Landscapes Covalent functionalization of G protein-coupled receptors by small molecular probes A deadly taste: linking bitter taste receptors and apoptosis Molecular roles in membrane receptor signaling pathways and cascade reactions in chondrocytes: a review Is GCR1 the GPR157 of plants? Structural and Molecular Insights into GPCR Function Structural insights into prolactin-releasing peptide receptor signaling and G-protein coupling selectivity Decoding the structural basis of ligand recognition and biased signaling in the motilin receptor 🔎 GPCR KEYWORDS GPCR , structural biology , biased signaling , metabolism , Chondrocytes , Signaling pathway , Integrin , Taste family 2 receptors , Calcium , Cell death , Mitochondria , macrolide antibiotics , motilin receptor , azithromycin , Extraoral taste receptors . < Previous Next >

Awkward... This page isn’t available. Go Home

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

Time Out This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon. Go Back

The Practical Assessment of Signaling Bias Dr. Terry Kenakin < Back Workshop Summary Join Dr. Terry Kenakin , a leading expert in pharmacology, as he unpacks the fascinating world of signaling bias in drug development! 🚀 This workshop will explore how different ligands (compounds) can stabilize unique receptor conformations, leading to distinct signaling outcomes—even when binding to the same receptor. Dr. Kenakin will explain that bias is not an exception but a fundamental principle of pharmacology, occurring whether or not researchers actively seek it. Through an engaging discussion, you'll explore: 🔹 What signaling bias is and why it matters 🔹 How receptor dynamics shape drug responses 🔹 Cutting-edge methods for quantifying bias 📊 🔹 Strategies to harness bias for better drug design —maximizing efficacy while minimizing side effects The session wraps up with a lively Q&A , allowing attendees to explore this game-changing topic in greater depth. Don't miss this opportunity to refine your understanding of bias as a tool, not an obstacle, in pharmacology! Key Highlights 🔍 Bias is Everywhere : Signaling bias naturally occurs in pharmacology—whether we look for it or not! 🧬 Receptor Flexibility : Ligands stabilize different receptor states, creating unique signaling pathways. 📏 Measuring Bias : New techniques allow us to quantify bias and compare drug efficacy more precisely. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific effects while avoiding unwanted side effects. 🗣️ Interactive Q&A : The discussion wraps up with an insightful Q&A, tackling real-world drug development challenges. Deep Dives & Insights 📌 Bias is Not an Anomaly—It’s a Feature! 🔹 Instead of avoiding bias, researchers can embrace it to refine drug responses. Dr. Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes. 📌 Receptors are Dynamic Players 🔹 Different ligands trigger unique receptor states, meaning the same receptor can signal in entirely different ways depending on what binds to it. Understanding these shifts can revolutionize drug development! 📌 Measuring Bias: A Quantitative Approach 🔹 The operational model provides a structured way to measure bias, combining affinity and efficacy. This allows for a side-by-side comparison of how different compounds influence receptor signaling. 📌 Bridging the Gap: Lab to Clinic 🔹 While measuring bias in a lab is relatively straightforward, translating these findings to clinical applications remains a challenge . The talk explores how to navigate this crucial gap. 📌 The Future of Drug Development 🚀 🔹 By integrating bias into drug design , researchers can craft more selective, effective, and safer therapies. This approach is shaping the next generation of precision medicine! Dr. Terry Kenakin’s workshop offers a fresh perspective on drug discovery . It shows that bias isn’t something to avoid—it’s something to utilize ! Whether you're a researcher, student, or industry professional, this session is packed with insights that will make you rethink your approach to pharmacology . Ready to explore the future of biased drug design? Let’s dive in! 🔬✨ AI Summary - May contain inaccuracies Materials: BIAS_WORKSHOP_PRINT .pdf Download PDF • 9.11MB BIAS_EXERCISE .pdf Download PDF • 721KB What would you like to learn today?